


PRECISION AND FUTURE MEDICINE

Cav-1, PDE-5 inhibitor, and moyamoya disease



Supplementary Fig. 2. Cycle guanosine monophosphate (cGMP) level after S-nitrosoglutathione (GSNO) treatment. Enzyme-linked immunosorbent assay (ELISA) was performed to determine appropriate concentration of GSNO in (A) human umbilical vessel endothelial cell (HUVEC) and (B) coronary artery smooth muscle cell (CASMC).